Who we are

Cann Group is a world-class Australian B2B medicinal cannabis company, focused on breeding, cultivating, manufacturing and supplying medicinal cannabis.

As the first company to receive an Australian Cannabis research license and a Cultivation license, Cann has years of experience in delivering research, cultivation and GMP manufacturing. At our R&D facility in Melbourne and our state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria, Cann Group is helping to lead Australian plant genetics, breeding, analysis and production techniques. Our experience and expertise allows us to achieve supply of high quality, safe medicinal cannabis for a range of medical conditions. Cann’s product portfolio includes its proprietary Satipharm delivery system for cannabinoids.

Cann Group is pursuing a full service business model with supply agreements, collaboration agreements, resources and capabilities that will enable it to be Australia’s premier B2B supplier. 

Cann’s Board and management have extensive experience in the pharmaceutical, biotech, agriculture and agronomy with expertise in commercialising pharmaceuticals and agricultural technology.  

Established in 2014, Cann Group is the first company to be issued with a Cannabis Research Licence by the Australian Government’s Office of Drug Control (ODC) in February 2017. This Licence authorises Cann to cultivate cannabis (in association with a relevant permit) for research purposes. In addition, in March 2017, Cann Group was issued Australia’s first Medicinal Cannabis Cultivation Licence, which authorised Cann to produce Australian-grown cannabis (in association a relevant permit) for medicinal purposes.